We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Senseonics Holdings, Inc. (SENS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.5010 |
| Open | 0.4971 |
| Bid | 0.4872 x 1000 |
| Ask | 0.4951 x 1000 |
| Day's Range | 0.4800 - 0.5038 |
| 52 Week Range | 0.4610 - 1.0500 |
| Volume | |
| Avg. Volume | 2,485,377 |
| Market Cap | 255.251M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.63 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SENS
Related Research
- Senseonics Holdings, Inc.Analyst Report: Medtronic PLCWith operational headquarters in Minnesota, Medtronic is one of the world's largest medical technology and solutions companies. Its devices focus on cardiac rhythm management, spinal and surgical navigation technologies, treatments for diabetes and neurological conditions, vascular therapies, and cardiac surgery. MDT is a component of the S&P 500.RatingFair ValueEconomic Moat2 days agoArgus Research
PR NewswireSAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
Ascensia Diabetes Care, a global diabetes care company and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have announced a significant extension of the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversen
Business WireSenseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
GERMANTOWN, Md., March 08, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes ("ATTD") in Florence, Italy.
Business WireSenseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
GERMANTOWN, Md., March 06, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.
Insider MonkeySenseonics Holdings, Inc. (AMEX:SENS) Q4 2023 Earnings Call Transcript
Senseonics Holdings, Inc. (AMEX:SENS) Q4 2023 Earnings Call Transcript February 29, 2024 Senseonics Holdings, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.04. SENS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good evening and welcome to the […]
- Thomson Reuters StreetEvents
Q4 2023 Senseonics Holdings Inc Earnings Call
Q4 2023 Senseonics Holdings Inc Earnings Call
ZacksSenseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates
Senseonics (SENS) delivered earnings and revenue surprises of 25% and 4.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireSenseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
GERMANTOWN, Md., February 29, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2023.
Business WireSenseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., February 15, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, February 29, 2024.
MedTech DiveSenseonics gains expanded Medicare coverage for implantable CGM
Three Medicare Administrative Contractors will start covering the Eversense E3 CGM for people who only take basal insulin.
- PR Newswire
MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM
Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable C
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| BNGO Bionano Genomics, Inc. | |||
| ZOM Zomedica Corp. | |||
| NNDM Nano Dimension Ltd. | |||
| OCGN Ocugen, Inc. | |||
| CTRM Castor Maritime Inc. |
Similar to SENS
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| ZOM Zomedica Corp. | |||
| ASXC Asensus Surgical, Inc. | |||
| DXCM DexCom, Inc. | |||
| TNDM Tandem Diabetes Care, Inc. | |||
| PACB Pacific Biosciences of California, Inc. |
Analyst Price Targets (3)
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/11/2024 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2023 | |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/15/2023 | |
| Initiated | Jefferies: to Underperform | 7/19/2023 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/11/2023 | |
| Maintains | HC Wainwright & Co.: to Buy | 7/25/2022 |
Company Profile
20451 Seneca Meadows Parkway
Germantown, MD 20876-7005
United States
301 515 7260
https://www.senseonics.com
Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 132
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
